143 related articles for article (PubMed ID: 1974725)
41. Predicting progression to AIDS: combined usefulness of CD4 lymphocyte counts and p24 antigenemia.
MacDonell KB; Chmiel JS; Poggensee L; Wu S; Phair JP
Am J Med; 1990 Dec; 89(6):706-12. PubMed ID: 1979205
[TBL] [Abstract][Full Text] [Related]
42. Relation between plasma concentrations of didanosine and markers of antiviral efficacy in adults with AIDS or AIDS-related complex.
Beltangady M; Knupp CA; Gustafson N; Barbhaiya RH; Dolin R; Seidlin M; Cooley TP; Rozencweig M
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S26-31. PubMed ID: 8093845
[TBL] [Abstract][Full Text] [Related]
43. T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS.
Levacher M; Tallet S; Dazza MC; Dournon E; Rouveix B; Pocidalo JJ
Clin Exp Immunol; 1990 Aug; 81(2):177-82. PubMed ID: 1696859
[TBL] [Abstract][Full Text] [Related]
44. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex.
Pinching AJ; Helbert M; Peddle B; Robinson D; Janes K; Gor D; Jeffries DJ; Stoneham C; Mitchell D; Kocsis AE
J Infect; 1989 Jan; 18 Suppl 1():33-40. PubMed ID: 2521663
[TBL] [Abstract][Full Text] [Related]
45. Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration.
Liebman HA; Cooley TP
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S52-8. PubMed ID: 8093847
[TBL] [Abstract][Full Text] [Related]
46. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
Kelleher T; Cross A; Dunkle L
Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
[TBL] [Abstract][Full Text] [Related]
47. Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.
Chaisson RE; Leuther MD; Allain JP; Nusinoff-Lehrman S; Boone GS; Feigal D; Volberding P
Arch Intern Med; 1988 Oct; 148(10):2151-3. PubMed ID: 3263098
[TBL] [Abstract][Full Text] [Related]
48. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.
Faulds D; Brogden RN
Drugs; 1992 Jul; 44(1):94-116. PubMed ID: 1379914
[TBL] [Abstract][Full Text] [Related]
49. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
[TBL] [Abstract][Full Text] [Related]
50. A randomized trial (ISS 901) of switching to didanosine versus continued zidovudine after the diagnosis of AIDS.
Vella S; Floridia M; Dally LG; Tomino C; Fragola V; Weimer LE; Milazzo F; Mazzotta F; Moroni M; Pastore G; Scalise G; Sinicco A; Ortona L; De Rienzo B; Dianzani F
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):462-9. PubMed ID: 8757422
[TBL] [Abstract][Full Text] [Related]
51. Response of serum p24 antigen and antibody to p24 antigen in patients with AIDS and AIDS-related complex treated with zidovudine.
Williams IG; Gabriel G; Kelly G; Loveday C; Tedder RS; Weller IV
AIDS; 1990 Sep; 4(9):909-12. PubMed ID: 2123627
[TBL] [Abstract][Full Text] [Related]
52. HIV antigen variability in ARC/AIDS.
Hendrix CW; Volberding PA; Chaisson RE
J Acquir Immune Defic Syndr (1988); 1991; 4(9):847-50. PubMed ID: 1910082
[TBL] [Abstract][Full Text] [Related]
53. Passive immunization in ARC and AIDS.
Karpas A; Gray J; Byron N; Gilgen D; Bally V; Oates JK; Gazzard B
Biotherapy; 1990; 2(2):159-72. PubMed ID: 2144762
[No Abstract] [Full Text] [Related]
54. Detection of infectious immune complexes in human immunodeficiency virus type 1 (HIV-1) infections: correlation with plasma viremia and CD4 cell counts.
Fiscus SA; Wallmark EB; Folds JD; Fryer J; van der Horst CM
J Infect Dis; 1991 Oct; 164(4):765-9. PubMed ID: 1680137
[TBL] [Abstract][Full Text] [Related]
55. New developments in the clinical use of didanosine.
Kahn J
J Acquir Immune Defic Syndr (1988); 1993; 6 Suppl 1():S47-50. PubMed ID: 8426301
[TBL] [Abstract][Full Text] [Related]
56. Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
Merigan TC; Skowron G
Am J Med; 1990 May; 88(5B):11S-15S. PubMed ID: 2159703
[TBL] [Abstract][Full Text] [Related]
57. Use of didanosine in zidovudine-intolerant patients infected with human immunodeficiency virus.
Nelson MR; Moyle GJ; Gazzard BG
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S59-62. PubMed ID: 8093848
[TBL] [Abstract][Full Text] [Related]
58. A randomized trial (ISS 902) of didanosine versus zidovudine in previously untreated patients with mildly symptomatic human immunodeficiency virus infection.
Floridia M; Vella S; Seeber AC; Tomino C; Fragola V; Weimer LE; Ricciardulli D; Milazzo F; Gritti FM; Mazzotta F; Ranieri S; Chiodo F; Moroni M; Cargnel A; Bassetti D; Giannini V; Cremoni L; Concia E; Sinicco A; Carosi G; Alberici F; Dianzani F
J Infect Dis; 1997 Feb; 175(2):255-64. PubMed ID: 9203645
[TBL] [Abstract][Full Text] [Related]
59. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
Whitfield RM; Bechtel LM; Starich GH
Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
[TBL] [Abstract][Full Text] [Related]
60. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine.
Allan JD; Connolly KJ; Fitch H; Jackson-Pope L; McLaren C; Canetta R; Groopman JE
Clin Infect Dis; 1993 Feb; 16 Suppl 1():S46-51. PubMed ID: 8425019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
